首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1475211

全球促紅血球生成素藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Erythropoietin Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球促紅血球生成素藥物市場需求預計將從2023年的89.7億美元達到2032年近131.1億美元的市場規模，2024-2032年研究期間的複合年成長率為4.31%。

促紅血球生成素藥物是一種模仿內源性促紅血球生成素作用的藥劑，內源性紅血球生成素是一種由腎臟產生的激素，控制骨髓中紅血球的生成。這些藥物用於治療與慢性腎臟病、癌症化療、愛滋病毒/愛滋病以及其他導致紅血球生成減少或紅血球損失增加的疾病相關的貧血。這些藥物有助於增加血紅素水平，提高氧氣輸送能力，緩解疲勞和虛弱等貧血症狀，並減少紅血球生成功能受損患者的輸血需求。

市場動態

慢性腎臟病 (CKD)、癌症相關貧血和其他血液疾病的發生率不斷上升，推動了對促紅血球生成素藥物的需求，將其作為刺激紅血球生成、控制貧血症狀和改善患者生活品質的基本治療方法。由於人口老化、生活方式相關疾病以及慢性病患病率上升等因素造成全球貧血負擔，人們越來越需要有效的促紅血球生成素療法，為患者提供有針對性的個人化治療選擇。此外，生物製藥製造、蛋白質工程和藥物傳輸技術的進步使得能夠開發出具有改進的藥物動力學、穩定性和功效特徵的下一代促紅血球生成素藥物，從而增強其治療潛力和臨床實用性。此外，促紅血球生成素療法的應用範圍不斷擴大，超越了運動醫學、傷口癒合和神經保護等傳統適應症，推動了對新型促紅血球生成素製劑和輸送系統的需求，這些製劑和輸送系統可以解決未滿足的醫療需求，並為不同的患者群體提供創新的解決方案。

此外，全球臨床實踐和醫療保健系統中擴大採用生物學名藥、生物改良劑和新型紅血球生成促效劑(ESA)，推動了市場競爭、定價動態和促紅血球生成素藥物的獲取，為藥品製造商、醫療保健提供者、和病人。隨著人們越來越關注基於價值的醫療保健、以患者為中心的方法和循證醫學，需要製定全面的策略來最佳化促紅血球生成素治療結果、確保患者安全並提高醫療保健系統效率。然而，專利到期、學名藥競爭和定價壓力可能會挑戰未來幾年的市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球促紅血球生成素藥物市場的各個細分市場進行了包容性評估。促紅血球生成素藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

促紅血球生成素藥物市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

按藥物類別

阿爾法依泊汀
BETA依泊汀
達貝泊汀阿爾法
其他

依藥物類型

生物製劑
生物相似藥

按藥物應用

癌症
腎臟疾病
血液學
神經病學
其他

按配銷通路

醫院藥房
零售藥房
網路藥房

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲促紅血球生成素藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。促紅血球生成素藥物市場的主要參與者包括安進公司、諾華公司、羅氏公司、葛蘭素史克、默克公司、強生公司、沃克哈特有限公司、輝瑞公司、百康有限公司.，梯瓦製藥工業有限公司。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業動態
波特五力分析
市場吸引力分析
- 按藥品類別分類的市場吸引力分析
- 按藥物類型分類的市場吸引力分析
- 按藥物應用分類的市場吸引力分析
- 按配銷通路分類的市場吸引力分析
- 市場吸引力分析：按地區

第 4 章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第 5 章：全球促紅血球生成素藥物市場分析：依藥物類別

按藥物類別概述
歷史和預測數據
按藥物類別分析
阿爾法依泊汀
BETA依泊汀
達貝泊汀阿爾法
其他

第 6 章：全球促紅血球生成素藥物市場分析：依藥物類型

按藥物類型概述
歷史和預測數據
依藥物類型分析
生物製劑
生物相似藥

第 7 章：全球促紅血球生成素藥物市場分析：依藥物應用分類

按藥物應用概述
歷史和預測數據
按藥物應用分析
癌症
腎臟疾病
血液學
神經病學
其他

第 8 章：全球促紅血球生成素藥物市場分析：按分銷管道

配銷通路概覽
歷史和預測數據
按配銷通路分析
醫院藥房
零售藥房
網路藥房

第 9 章：全球促紅血球生成素藥物市場分析：依地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 10 章：促紅血球生成素藥物公司的競爭格局

促紅血球生成素藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 11 章：公司簡介

頂級公司市佔率分析
市場集中度
Amgen Inc.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche Ltd.

公司簡介
公司收入
產品
最近的發展

公司簡介
公司收入
產品
最近的發展

Merck & Co. Inc.

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson

公司簡介
公司收入
產品
最近的發展

Wockhardt Ltd.

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Biocon Ltd.

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd.

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114340

The global demand for Erythropoietin Drugs Market is presumed to reach the market size of nearly USD 13.11 Billion by 2032 from USD 8.97 Billion in 2023 with a CAGR of 4.31% under the study period 2024 - 2032.

Erythropoietin drugs are pharmaceutical agents that mimic the action of endogenous erythropoietin, a hormone produced by the kidneys that controls the generation of red blood cells in the bone marrow. These drugs are used to treat anemia associated with chronic kidney disease, cancer chemotherapy, HIV/AIDS, and other medical conditions that result in reduced red blood cell generation or heightened loss of red blood cells. These drugs help increase hemoglobin levels, improve oxygen transport capacity, alleviate symptoms of anemia such as fatigue and weakness, and reduce the need for blood transfusions in patients with compromised erythropoietic function.

MARKET DYNAMICS

The escalating incidence of chronic kidney disease (CKD), cancer-related anemia, and other hematological disorders drives the demand for erythropoietin drugs as essential treatments to stimulate red blood cell production, manage anemia symptoms, and improve patients' quality of life. With factors such as aging populations, lifestyle-related diseases, and the rising prevalence of chronic conditions contributing to the global burden of anemia, there is a growing need for effective erythropoietin therapies that offer targeted and personalized treatment options for patients. Additionally, advancements in biopharmaceutical manufacturing, protein engineering, and drug delivery technologies enable the development of next-generation erythropoietin drugs with improved pharmacokinetics, stability, and efficacy profiles, enhancing their therapeutic potential and clinical utility. Moreover, the expanding applications of erythropoietin therapy beyond traditional indications, such as sports medicine, wound healing, and neuroprotection, drive the demand for novel erythropoietin formulations and delivery systems that address unmet medical needs and offer innovative solutions for diverse patient populations.

Furthermore, the increasing adoption of biosimilars, biobetters, and novel erythropoiesis-stimulating agents (ESAs) in clinical practice and healthcare systems worldwide drives market competition, pricing dynamics, and access to erythropoietin drugs, creating opportunities and challenges for drug manufacturers, healthcare providers, and patients. With the growing focus on value-based healthcare, patient-centered approaches, and evidence-based medicine, there is a need for comprehensive strategies that optimize erythropoietin therapy outcomes, ensure patient safety, and enhance healthcare system efficiency. However, patent expirations, generic competition, and pricing pressures may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of erythropoietin drugs. The growth and trends of erythropoietin drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the erythropoietin drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Others

By Drug Type

Biologics
Biosimilar

By Drug Application

Cancer
Renal Disease
Hematology
Neurology
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Erythropoietin Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Erythropoietin Drugs market include Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., GSK, Merck & Co., Inc., Johnson & Johnson, Wockhardt Ltd., Pfizer, Inc., Biocon Ltd., Teva Pharmaceutical Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ERYTHROPOIETIN DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Drug Type
- 3.7.3 Market Attractiveness Analysis By Drug Application
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data
5.3. Analysis By Drug Class
5.4. Epoetin Alfa Historic and Forecast Sales By Regions
5.5. Epoetin Beta Historic and Forecast Sales By Regions
5.6. Darbepoetin Alfa Historic and Forecast Sales By Regions
5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY DRUG TYPE

6.1. Overview By Drug Type
6.2. Historical and Forecast Data
6.3. Analysis By Drug Type
6.4. Biologics Historic and Forecast Sales By Regions
6.5. Biosimilar Historic and Forecast Sales By Regions

7. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY DRUG APPLICATION

7.1. Overview By Drug Application
7.2. Historical and Forecast Data
7.3. Analysis By Drug Application
7.4. Cancer Historic and Forecast Sales By Regions
7.5. Renal Disease Historic and Forecast Sales By Regions
7.6. Hematology Historic and Forecast Sales By Regions
7.7. Neurology Historic and Forecast Sales By Regions
7.8. Others Historic and Forecast Sales By Regions

8. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data
8.3. Analysis By Distribution Channel
8.4. Hospital Pharmacy Historic and Forecast Sales By Regions
8.5. Retail Pharmacy Historic and Forecast Sales By Regions
8.6. Online Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ERYTHROPOIETIN DRUGS COMPANIES

10.1. Erythropoietin Drugs Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF ERYTHROPOIETIN DRUGS INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Amgen Inc.
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Novartis AG
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. F. Hoffmann-La Roche Ltd.
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. GSK
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Merck & Co. Inc.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Johnson & Johnson
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Wockhardt Ltd.
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Pfizer Inc.
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Biocon Ltd.
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Teva Pharmaceutical Industries Ltd.
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments